Medications

Daclatasvir for hepatitis C: Added benefit not proven

The drug daclatasvir (trade name Daklinza) has been available since August 2014 for the treatment of adults with chronic hepatitis C (CHC) infection. The German Institute for Quality and Efficiency in Health Care (IQWiG) ...

Oncology & Cancer

Sorafenib effect on HCC survival depends on hepatitis status

(HealthDay)—For patients with advanced unresectable hepatocellular carcinoma, the effect of sorafenib on overall survival (OS) is dependent on patients' hepatitis status, according to a meta-analysis published online Jan. ...

Diseases, Conditions, Syndromes

Predicting the outcome of hepatitis C virus treatment

Millions of people throughout the world are infected with hepatitis C virus (HCV), which can lead to cirrhosis of the liver and cancer. Directly acting antiviral agents inhibit viral proteins and have been used to successfully ...

Diseases, Conditions, Syndromes

CDC: Proportion of increased-risk deceased organ donors on rise

(HealthDay)—Among deceased organ donors, there has been an increase in the proportion at increased risk for transmitting hepatitis B virus (HBV), hepatitis C virus (HCV), and HIV to recipients, according to research published ...

Diseases, Conditions, Syndromes

Improvements needed for hepatitis C testing in youth

A new study led by Boston Medical Center uncovered a need to improve testing rates for Hepatitis C Virus (HCV) in young people, specifically those with documented substance use history. In the national data sample, under ...

page 34 from 40